Replies to post #3335 on Innovus Pharmaceuticals Inc. (fka INNV)

[ShawnP123]

pennies- I found the last paragraph interesting which is a definate conflict with what the company is saying:


"As ever, we’re almost definitely going to see some level of dilution between now and a Fluticare commercialization push, purely to generate the capital required to execute on a marketing strategy. Cash is low, and revenues not nearly enough to fund operations post-approval. We think that this dilution can be offset by value-added if the company can snap up a small portion of the nasal spray market, however, and therein lies our bias."

They are stating company will need to raise additional capital if and when Fluticare is approved via dilution of stock.

I had stated that concern some time ago but was rebuffed by their revolving line of credit (which, IMO, is not enough) for the production capital needed to support Fluticare.

However, the dilution (if it happens) could be offset by substantial revenue gains. Won't know that until 45 to 50 days after close of Q2 2017.